RxDoctor Payments Data

Reggie Thomes, DO

Hematology & Oncology · la Crosse, WINPI 1457713448

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,658 of the $11,548 with a category attached, or 83.6%. Sanofi accounts for 93.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $7,718 and has fallen 79.0% since, to $1,618 in 2025.

$11,548in general payments, 2019–2025

Across 21 payments — averaging $549.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$11K
  • Recordati_rare_diseases_inc.$280
  • Johnson & Johnson$207
  • Bristol Myers Squibb$120
  • Rigel Pharmaceuticals, Inc.$106
$22,527in research payments, 2019–2025

Across 1 payment — averaging $22,527 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$23K

What the payments were for

  • Consulting fees$9,65884%
  • Travel & lodging$1,14310%
  • Food & beverage$6656%
  • Education$821%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,548 in reported general payments places this provider in the 80th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin →

Medicare billing

Part B allowed, 2024
$72,115
Medicare patients
254
Services billed
7,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide50$903,483
BrukinsaZanubrutinib55$794,140
XtandiEnzalutamide12$167,183
VenclextaVenetoclax24$159,227
PegasysPeginterferon Alfa-2a13$56,593
EliquisApixaban50$45,287
Posaconazole23$17,932
Abiraterone Acetate12$1,844
Hydroxyurea55$1,715
Acyclovir169$1,682
Potassium Chloride24$463
Allopurinol32$319
Duloxetine Hcl17$298
Levofloxacin17$225
Prochlorperazine Maleate14$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$120$903,48350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in la Crosse

See the full list for Wisconsin →

Where these figures come from

Is this you, or does something look wrong? →